Common use of Abstracts and Posters Clause in Contracts

Abstracts and Posters. If a Party intends to present findings with respect to the Product in the Field at symposia or other meetings of healthcare professionals, or international and/or US or European congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”), to the extent permitted by applicable laws, such Party through the JSC or its designee shall provide to the other, prior to submission or presentation, as the case may be, copies of (i) all abstracts that will be submitted for publication in connection with (a) any international Scientific Meeting, in any Scientific Meeting in the European Union or in the United States and, (b) with respect to Partner, any Scientific Meeting within or without the Partner Territory and (c) with respect to Bioprojet, any Scientific Meeting in the Partner Territory and in the European Union and (ii) all posters that will be presented at such Scientific Meeting, in each case, concerning the Product which have been prepared by or on behalf of one of the Parties, for submission or presentation. Commencing with the receipt of any such abstract or poster the receiving Party shall have five (5) business days in the case of an abstract, or ten (10) business days in the case of a poster, to inform the sending Party of its observations and suggestions with respect thereto (it being understood that, during such review period, as applicable, no submission or presentation thereof shall take place) and the Parties shall discuss these observations and suggestions. The Party proposing to publish such an abstract or make such a presentation shall, in good faith, consider the comments made by the other Party, particularly if disclosure may be prejudicial to the other Party’s opportunity to obtain any patent rights. A Party will not publish or present any Confidential Information of the other Party without such other Party’s prior written consent. The sending Party shall provide to the receiving Party copies of (i) all final abstracts as soon as reasonably practicable after the approval of the Scientific Meeting, and (ii) all final posters accepted for publication or to be presented five (5) business days prior to the planned publication or presentation thereof (upon availability and distribution of such information assuming that providing such information is acceptable taking into consideration the publishers’ need to comply with any healthcare compliance guidelines). The Parties shall use good faith and commercially reasonable efforts to provide the other Party with draft slide presentations in accordance with the foregoing time periods.

Abstracts and Posters. If a Party intends to present findings with respect to the any Licensed Product in the Field at symposia or other meetings of healthcare professionals, or international and/or US international, national or European regional congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”), to the extent permitted by applicable lawsLaws, such Party through the JSC or its designee shall provide to the other, prior to submission or presentation, as the case may be, copies of (i) all abstracts that will be submitted for publication in connection with (a) with any international Scientific Meeting, in any Scientific Meeting in the European Union or in the United States and, (b) with respect to PartnerPfizer, any Scientific Meeting within or without in the Partner Servier Territory and any major Scientific Meetings in the Pfizer Territory and (c) with respect to BioprojetServier, any Scientific Meeting in the Partner Pfizer Territory and any Scientific Meeting in the European Union Servier Territory (a list of which Scientific Meetings will be established by Servier and reviewed from time to time by the Parties) and (ii) all posters that will be presented at such Scientific Meeting, in each case, concerning the any Licensed Product which have been prepared by or on behalf of one of the Parties, for submission or presentation. Commencing with the receipt of any such abstract or poster the receiving Party shall have five (5) business days in the case of an abstract, or ten (10) business days in the case of a poster, [***] Business Days to inform the sending Party of its observations and suggestions with respect thereto (it being understood that, during that the Party proposing to publish such review period, as applicable, no abstract or poster shall submit it to the receiving Party at least [***] Business Days prior to the planned submission or presentation thereof shall take placefor publication) and the Parties shall discuss these observations and suggestions. The Party proposing to publish such an abstract or make such a presentation shall, in good faith, consider the comments made by the other Party, particularly if disclosure may be prejudicial to the other Party’s opportunity to obtain any patent rights. A Party will not publish or present any Confidential Information of the other Party without such other Party’s prior written consent. The sending Party shall provide to the receiving Party copies of (i) all final abstracts as soon as reasonably practicable after the approval of the Scientific Meeting, and (ii) all final posters accepted for publication or to be presented five (5) business days [***] Business Days prior to the planned publication or presentation thereof (upon availability and distribution of such information assuming that providing such information is acceptable taking into consideration the publishers’ need to comply with any healthcare compliance guidelines). The Parties shall use good faith and commercially reasonable efforts to provide the other Party with draft slide presentations in accordance with the foregoing time periods.

Abstracts and Posters. If a Party intends to present findings with respect to the any Licensed Compound or Licensed Product in the Field at symposia or other meetings of healthcare professionals, or international and/or US or European congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”), to the extent permitted by applicable lawsApplicable Laws, such Party through the JSC or its designee shall provide to the other, prior to submission or presentation, as the case may be, copies of (i) all abstracts that will be submitted for publication in connection with (a) any international Scientific Meeting, in any Scientific Meeting in the European Union or in the United States and, (b) with respect to PartnerCTI, any Scientific Meeting within or without in the Partner SERVIER Territory and any major Scientific Meetings in the CTI Territory and (c) with respect to BioprojetSERVIER, any Scientific Meeting in the Partner CTI Territory and any Scientific Meeting in the European Union SERVIER key markets, as reasonably determined by SERVIER and (ii) all posters that will be presented at such Scientific Meeting, in each case, concerning the Licensed Compound or Licensed Product which have been prepared by or on behalf of one of the Parties, for submission or presentation. Commencing with the receipt of any such abstract or poster poster, the receiving Receiving Party shall have five (5) business days Business Days in the case of an abstract, or ten (10) business days Business Days in the case of a poster, to inform the sending Party of its observations and suggestions with respect thereto (it being understood that, during such review period, as applicable, no submission or presentation thereof shall take place) ), and the Parties shall discuss these observations and suggestions. The Party proposing to publish such an abstract or make such a presentation shall, in good faith, consider the comments made by the other Party, particularly if disclosure may be prejudicial to the other Party’s opportunity to obtain any patent rights. A Party will not publish or present any Confidential Information of the other Party without such other Party’s prior written consent. The sending Party shall provide to the receiving Receiving Party copies of (i) all final abstracts as soon as reasonably practicable after the approval of the Scientific Meeting, and (ii) all final posters accepted for publication or to be presented five (5) business days Business Days prior to the planned publication or presentation thereof (upon availability and distribution of such information assuming that providing such information is acceptable taking into consideration the publishers’ need to comply with any healthcare compliance guidelines). The Parties shall use good faith and commercially reasonable efforts to provide the other Party with draft slide presentations in accordance with the foregoing time periods.that

Abstracts and Posters. If a Party intends to present findings with respect to the any Licensed Compound or Licensed Product in the Field at symposia or other meetings of healthcare professionals, or international and/or internationaland/or US or European congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”), to the extent permitted by applicable lawsApplicable Laws, such Party through the JSC or its designee shall provide to the other, prior to submission or presentation, as the case may be, copies of (i) all abstracts that will be submitted for publication in connection with (a) any international Scientific Meeting, in any Scientific Meeting in the European Union or in the United States and, (b) with respect to PartnerCTI, any Scientific Meeting within or without in the Partner Servier Territory and any major Scientific Meetings in the CTI Territory and (c) with respect to BioprojetServier, any Scientific Meeting in the Partner CTI Territory and in the European Union any Scientific Meeting ** (a list of which Scientific Meetings will be established and updated from time to time by a publication Additional Committee) and (ii) all posters that will be presented at such Scientific Meeting, in each case, concerning the Licensed Compound or Licensed Product which have been prepared by or on behalf of one of the Parties, for submission or presentation. Commencing with the receipt of any such abstract or poster the receiving Receiving Party shall have five (5) business days ** in the case of an abstract, or ten (10) business days ** in the case of a poster, to inform the sending Party of its observations and suggestions with respect thereto (it being understood that, during such review period, as applicable, no submission or presentation thereof shall take place) and the Parties shall discuss these observations and suggestions. The Party proposing to publish such an abstract or make such a presentation shall, in good faith, consider the comments made by the other Party, particularly if disclosure may be prejudicial to the other Party’s opportunity to obtain any patent rights. A Party will not publish or present any Confidential Information of the other Party without such other Party’s prior written consent. The sending Party shall provide to the receiving Receiving Party copies of (i) all final abstracts as soon as reasonably practicable ** after the approval of the Scientific Meeting, and (ii) all final posters accepted for publication or to be presented five (5) business days ** prior to the planned publication or presentation thereof (upon availability and distribution of such information assuming that providing such information is acceptable taking into consideration the publishers’ need to comply with any healthcare compliance guidelines). The Parties shall use good faith and commercially reasonable efforts Commercially Reasonable Efforts to provide the other Party with draft slide presentations in accordance with the foregoing time periods.

Abstracts and Posters. If a Party intends to present findings with respect to the any Licensed Compound or Licensed Product in the Field at symposia or other meetings of healthcare professionals, or international and/or US or European congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”), to the extent permitted by applicable lawsApplicable Laws, such Party through the JSC or its designee shall provide to the other, prior to submission or presentation, as the case may be, copies of (i) all abstracts that will be submitted for publication in connection with (a) any international Scientific Meeting, in any Scientific Meeting in the European Union or in the United States and, (b) with respect to PartnerCTI, any Scientific Meeting within or without in the Partner Servier Territory and any major Scientific Meetings in the CTI Territory and (c) with respect to BioprojetServier, any Scientific Meeting in the Partner CTI Territory and in the European Union any Scientific Meeting ** (a list of which Scientific Meetings will be established and updated from time to time by a publication Additional Committee) and (ii) all posters that will be presented at such Scientific Meeting, in each case, concerning the Licensed Compound or Licensed Product which have been prepared by or on behalf of one of the Parties, for submission or presentation. Commencing with the receipt of any such abstract or poster poster, the receiving Receiving Party shall have five (5) business days ** in the case of an abstract, or ten (10) business days ** in the case of a poster, to inform the sending Party of its observations and suggestions with respect thereto (it being understood that, during such review period, as applicable, no submission or presentation thereof shall take place) ), and the Parties shall discuss these observations and suggestions. The Party proposing to publish such an abstract or make such a presentation shall, in good faith, consider the comments made by the other Party, particularly if disclosure may be prejudicial to the other Party’s opportunity to obtain any patent rights. A Party will not publish or present any Confidential Information of the other Party without such other Party’s prior written consent. The sending Party shall provide to the receiving Receiving Party copies of (i) all final abstracts as soon as reasonably practicable ** after the approval of the Scientific Meeting, and (ii) all final posters accepted for publication or to be presented five (5) business days ** prior to the planned publication or presentation thereof (upon availability and distribution of such information assuming that providing such information is acceptable taking into consideration the publishers’ need to comply with any healthcare compliance guidelines). The Parties shall use good faith and commercially reasonable efforts Commercially Reasonable Efforts to provide the other Party with draft slide presentations in accordance with the foregoing time periods.

Abstracts and Posters. If a Each Party intends to present findings with respect to the Product in the Field at symposia or other meetings of healthcare professionals, or international and/or US or European congresses, conferences or meetings organized by a professional society or organization (any such occasion, a “Scientific Meeting”), to the extent permitted by applicable laws, such Party through the JSC or its designee shall provide to the other, prior to submission or presentation, as the case may be, copies of (i) all abstracts that will be submitted for publication in connection with (a) any international Scientific Meeting, in any or major national Scientific Meeting Amgen Ref. No. 2015641252 Page 53 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. in the European Union Territory or in outside of the United States andTerritory, (b) with respect to Partner, any Scientific Meeting within or without the Partner Territory and (c) with respect to Bioprojet, any Scientific Meeting in the Partner Territory and in the European Union and (ii) all posters and other materials (such as slides) that will be presented at such Scientific Meeting, in each case, concerning the a Licensed Product which have been prepared by or on behalf of one of the Parties, for submission or presentationpresentation outside or in the Territory. Commencing with the receipt of any such abstract or poster or oral presentation materials the receiving Party shall have five (5) business days in the case of an abstract, or ten (10) business days in the case of a poster, [*] Business Days to inform the sending Party of its observations and suggestions with respect thereto (thereto; it being understood that, during such review [*] Business Day period, as applicable, no submission or presentation thereof shall take place) place and the Parties shall discuss these observations and suggestions. The Party proposing to publish such an abstract or make such a presentation shall, in good faith, consider the comments made by the other Party, particularly if disclosure may be prejudicial to the other Party’s opportunity to obtain any patent rights. A Party will not publish submit in any abstract or present in any poster, other written materials or oral presentation any Confidential Information of the other Party without such other Party’s prior written consent. The sending Party shall provide to the receiving Party copies of (i) all final abstracts accepted for publication and all final posters to be presented [*] Business Days or as soon as reasonably practicable after the approval of the Scientific Meeting, and (ii) all final posters accepted for publication or to be presented five (5) business days prior to the planned publication or presentation thereof and oral presentations and accompanying written materials at least [*] Business Days prior to presentation (upon availability and distribution of such information assuming that providing such information is acceptable taking into consideration the publishers’ need to comply with any healthcare compliance guidelines). Each Party agrees that it will not unreasonably withhold, condition or delay its consent to requests for (i) extensions of the above timelines (in Sections 11.6 (Publications and Presentations) and 11.7 (Scientific Papers, Abstracts and Posters)) in the event that material late-breaking clinical data becomes available or (ii) shortening of the above timelines (in Sections 11.6 (Publications and Presentations) and 11.7 (Scientific Papers, Abstracts and Posters)) if the requesting Party has a good faith belief that circumstances warrant such acceleration. The Parties acknowledge and agree that all publications and presentations pursuant to Sections 11.6 (Publications and Presentations) and 11.7 (Scientific Papers, Abstracts and Posters) shall use good faith and commercially reasonable efforts to provide the other Party with draft slide presentations in accordance comply with the foregoing time periodsInternational Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.